Data gathered: January 10
Alternative Data for Kymera Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 10,000 | Sign up | Sign up | Sign up |
| Google Trends | 26 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 602 | Sign up | Sign up | Sign up |
| Twitter Mentions | 16 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
About Kymera Therapeutics
Kymera Therapeutics, Inc., a biopharmaceutical company, is focused on discovering and developing new small molecule treatments that selectively break down disease-causing proteins by harnessing the body's own natural protein breakdown system. The company is headquartered in Watertown, Massachusetts.
| Price | $40.52 |
| Target Price | Sign up |
| Volume | 322,140 |
| Market Cap | $2.62B |
| Year Range | $29.85 - $52.4 |
| Dividend Yield | 0% |
| Analyst Rating | 82% buy |
| Industry | Biotechnology |
In the news
 |
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Insider Sells $130,635.75 in StockJanuary 7 - ETF Daily News |
 |
Kymera Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14January 6 - Yahoo |
|
Comparing Kymera Therapeutics (NASDAQ:KYMR) & Vir Biotechnology (NASDAQ:VIR)December 31 - ETF Daily News |
|
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Average Rating of “Moderate Buy” from BrokeragesDecember 29 - ETF Daily News |
|
Leerink Partners Reaffirms “Outperform” Rating for Kymera Therapeutics (NASDAQ:KYMR)December 28 - ETF Daily News |
|
Franklin Resources Inc. Grows Stock Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR)December 28 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 3.7M | 16M | -12M | -62M | -72M | -0.820 |
| Q2 '24 | 26M | 18M | 7.9M | -42M | -51M | -0.580 |
| Q1 '24 | 10M | 20M | -9.5M | -49M | -57M | -0.620 |
| Q4 '23 | 48M | 15M | 33M | -14M | -19M | -0.250 |
| Q3 '23 | 4.7M | 15M | -9.8M | -53M | -52M | -0.900 |
Insider Transactions View All
| Chiniara Ellen filed to sell 54,826 shares at $41.8. January 6 '25 |
| Esposito Pamela filed to sell 7,150 shares at $47.7. September 17 '24 |
Similar companies
Read more about Kymera Therapeutics (KYMR) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions & customer reviews.
What is the Market Cap of Kymera Therapeutics?
The Market Cap of Kymera Therapeutics is $2.62B.
What is the current stock price of Kymera Therapeutics?
Currently, the price of one share of Kymera Therapeutics stock is $40.52.
How can I analyze the KYMR stock price chart for investment decisions?
The KYMR stock price chart above provides a comprehensive visual representation of Kymera Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Kymera Therapeutics shares. Our platform offers an up-to-date KYMR stock price chart, along with technical data analysis and alternative data insights.
Does KYMR offer dividends to its shareholders?
As of our latest update, Kymera Therapeutics (KYMR) does not offer dividends to its shareholders. Investors interested in Kymera Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Kymera Therapeutics?
Some of the similar stocks of Kymera Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.